Epigenetic Enhancement of Cognitive Training in Aging Mood Disorder Populations
NCT07404085 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 160
Last updated 2026-02-11
Summary
The aim of this clinical trial is to investigate the effects of a three-week virtual reality-based cognitive remediation training (VR-CRT) programme in combination with daily intake of a histone deacetylase inhibitor (HDACi) sodium butyrate on cognition in symptomatically stable patients with mood disorders (depression or bipolar disorder).
The investigators hypothesize that the VR-based cognitive remediation training (VR-CRT) combined with HDACi butyrate vs. a VR-based control treatment combined with placebo will improve global cognition (primary outcome measure) over three weeks.
Secondly, the investigators hypothesize that VR-CRT with placebo will improve cognition relative to the VR control treatment with placebo, although to a lesser extent than VR-CRT with HDACi butyrate.
Thirdly, the investigators hypothesize that the HDACi butyrate with VR control treatment will not produce cognitive improvements relative to placebo with VR control treatment.
Finally, the investigators hypothesize that the combined treatment (VR-CRT + HDACi butyrate) will enhance neuroplasticity (exploratory outcome) vs. VR control with placebo, as indicated by increase in hippocampal volume and/or memory-related activity shown with structural and functional MRI.
Conditions
- Bipolar Disorder (BD)
- Depression - Major Depressive Disorder
- Cognitive Impairment
Interventions
- BEHAVIORAL
-
Virtual Reality-based cognitive remediation therapy (VR-CRT)
VR-CRT on 360° Meta Quest 2-software in which participants train cognitive abilities guided by a therapist. The platform includes three immersive scenarios: (1) a kitchen scenario focusing on planning and cooking a meal, (2) a supermarket scenario focusing on grocery shopping and (3) a restaurant scenario focusing on remembering names and personal information. The virtual reality training is supported by a psychoeducation program that focuses on application of learned cognitive strategies in daily life.
- BEHAVIORAL
-
Virtual Reality-based control treatment (VR-CT)
VR-CT: The virtual reality control training involves completing different virtual reality games that are available through the Meta Quest games store. The chosen games involve no direct training of cognitive abilities such as planning skills og strategic learning, but merely involves simple reaction time and interaction with an entertaining environment that is meaningful to the participant and gives the impression of training cognitive skills.
- DIETARY_SUPPLEMENT
-
HDACi butyrate
Daily intake of sodium butyrate.
- DIETARY_SUPPLEMENT
-
Placebo
Daily intake of placebo.
Sponsors & Collaborators
-
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
lead OTHER
Principal Investigators
-
Kamilla Woznica Miskowiak, DMSc, DPhil · Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
-
Julian Macoveanu, PhD · Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 40 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-11-14
- Primary Completion
- 2027-07-01
- Completion
- 2028-07-01
Countries
- Denmark
Study Locations
More Related Trials
-
Effects of Erythropoietin for Cognitive Side-effects of ECT
NCT03339596 ·Status: COMPLETED ·Phase: PHASE2
-
Lethargic Depression Study
NCT00064467 ·Status: COMPLETED ·Phase: PHASE3
-
Dichotic Listening as a Predictor of Medication Response in Depression
NCT00404755 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Remote Monitoring in Patients Treated for Moderate to Severe Major Depressive Episodes
NCT07087353 ·Status: RECRUITING ·Phase: NA
-
A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication
NCT04937829 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Test Different Doses of BI 1569912 in People With Depression
NCT06558344 ·Status: COMPLETED ·Phase: PHASE2
-
BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder
NCT03193398 ·Status: COMPLETED ·Phase: PHASE2
-
A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD
NCT05414422 ·Status: COMPLETED ·Phase: PHASE2
-
The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder
NCT02749721 ·Status: COMPLETED ·Phase: PHASE4
-
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401 ·Status: RECRUITING ·Phase: PHASE3
-
Study to Treat Major Depressive Disorder With a New Medication
NCT03043560 ·Status: COMPLETED ·Phase: PHASE2
-
Cognitive Training as an Adjunct to Ketamine in Real-world Clinics
NCT06526078 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)
NCT03785652 ·Status: COMPLETED ·Phase: PHASE1
-
Memory Functioning and Antidepressant Treatment
NCT00296933 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
NCT06267846 ·Status: COMPLETED ·Phase: PHASE2
-
Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine
NCT05768126 ·Status: RECRUITING ·Phase: PHASE4
-
Advancing Personalized Antidepressant Treatment Using PET/MRI
NCT02623205 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder
NCT02279953 ·Status: COMPLETED ·Phase: PHASE3
-
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06963021 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
NCT01163266 ·Status: COMPLETED ·Phase: PHASE3
-
Vortioxetine for Post-COVID-19 Condition
NCT05047952 ·Status: COMPLETED ·Phase: PHASE2
-
rEEG Guided Pharmacotherapy of Subjects With Depression Treatment Failure
NCT00437827 ·Status: COMPLETED ·Phase: NA
-
Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)
NCT00759395 ·Status: COMPLETED ·Phase: PHASE2
-
Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease
NCT02454426 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Optimizing Electroconvulsive Therapy for Depression
NCT00045916 ·Status: COMPLETED ·Phase: PHASE4